Investor
CAXTON CORP
CIK 0001388551 · filed 2026-02-13 · SEC filing
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Spdr Gold Tr | — | 6.96K | $2.76M | 64.5% | — | Held |
| Berkshire Hathaway Inc Del | — | 710 | $356.8K | 8.3% | — | Held |
| Spyre Therapeutics, Inc. | SYRE | 8.92K | $292.2K | 6.8% | — | Held |
| Mind Medicine Mindmed Inc | — | 15.7K | $210.1K | 4.9% | — | Held |
| Kyverna Therapeutics, Inc. | KYTX | 18.8K | $176.5K | 4.1% | — | Held |
| Compass Therapeutics, Inc. | CMPX | 29.5K | $158.4K | 3.7% | — | Held |
| Lexeo Therapeutics, Inc. | LXEO | 13.9K | $138.5K | 3.2% | — | Held |
| X4 Pharmaceuticals, Inc | XFOR | 15.6K | $62.2K | 1.5% | — | Held |
| Inhibikase Therapeutics, Inc. | IKT | 28.5K | $58.3K | 1.4% | — | Held |
| Sab Biotherapeutics Inc | — | 10.5K | $39.4K | 0.9% | — | Held |
| Context Therapeutics Inc. | CNTX | 18.4K | $27.1K | 0.6% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.